Quantitative RT–PCR analysis of MCF-7 breast cancer cells showed that treatment with 5-AzadC or TSA gave a greater increase in MUC4 mRNA compared to treatment with 5-AzadC/TSA in combination (38.9-, 30.9- and 6.03-fold increases, respectively). This evidence concerns the gene MUC4 and breast carcinoma.